The clinical features of chronic beryllium disease (CBD) are similar to many other chronic lung diseases. In particular, it may be difficult to distinguish it from pulmonary sarcoidosis since the two conditions may be very alike in clinical, pathological and radiological features.
Introduction
Occupational exposure to beryllium is known to cause lesions in the skin, acute pneumonitis, sarcoid-like granulomata in the lungs and other organs, and chronic pulmonary fibrosis [1] [2] [3] [4] [5] [6] [7] . The pulmonary fibrosis of chronic beryllium disease (CBD) is the most serious of these conditions, and can lead to death. It is also the most important from the occupational health hazard perspective, as relatively low levels of exposure can lead to significant disability. In the past, the use of beryllia (beryllium oxide) in the fluorescent tube manufacturing industry resulted in many cases of CBD and its use in this application was subsequently discontinued [1, 2, 6] . The USA is the major producer of beryllium, with Brush Wellman being the leading producer of beryllium compounds in the USA. The range of industrial processes with potential occupational exposure to beryllium has expanded significantly in recent years. Industries where beryllium exposure can occur include: mining; extraction and smelting plants; the manufacture of beryllium alloys, chemicals and ceramics; the manufacture of electronic, defence and aerospace equipment, tools and dies, and golf clubs; and metallurgical operations [1, 2, 6] . Some current uses are in the making of air bag sensors, cell phones and computers [7] . There has been a resurgence of beryllium disease being reported from industries. This disease can take anywhere from a few months to 30 years to develop [8] [9] [10] . Lung cancer has also been associated with exposure to beryllium [3, 11] , but there has been a debate about the strength of the evidence [12] [13] [14] . The American Conference of Governmental Industrial Hygienists (ACGIH) has proposed in its notice of intended changes to lower its current threshold limit value (TLV) for beryllium of 0.002 mg/m 3 to 0.0002 mg/m 3 with a designation of A1 carcinogen, i.e. confirmed human carcinogen [3] . In the late 1980s, the advent of the beryllium lymphocyte proliferation test (BeLPT), the bronchoalveolar lavage lymphocyte proliferation test (BALLPT) and more sophisticated medical devices for examination of the lungs enhanced the ability of the medical community to identify early cases of CBD. BeLPT identifies workers who are sensitized to beryllium. In this test, cells from the blood or lung are cultured in the presence or absence of beryllium salts. Proliferation is measured by incorporation of a radioactive DNA precursor, tritiated thymidine ( 3 HdT). The results are expressed as a ratio of 3 HdT incorporation in berylliumstimulated and -unstimulated cells [4] . Many sensitized workers go on to develop CBD, but at the present time it is unclear as to whether all sensitized workers will eventually develop CBD. The US National Institute for Occupational Safety and Health (NIOSH) is presently conducting a study to determine whether genetic factors contribute to the development of CBD and evaluating the efficacy of screening in preventing adverse outcomes of the disease [5] . Today, the diagnostic criteria for CBD used in clinical practice are confirmed sensitization to beryllium and the presence of pulmonary granulomas in lung biopsies [6] .
The radiological and clinical features of CBD are similar to those of many other chronic lung diseases [1, 2] . In particular, it may be hard to distinguish from pulmonary sarcoidosis, since the clinical, pathological and radiological features of the two conditions may be very similar [1, 2] . Measuring the concentration of beryllium in the lungs may help distinguish between the two conditions. Recently, laser microprobe mass spectrometry was used to analyse beryllium in granulomas and it was shown to be possible to differentiate between CBD and sarcoidosis cases [15] . In this paper, we describe an investigation which measured the concentration of beryllium in the lungs of an autopsied case of CBD and compared it with the concentration in the lungs of autopsied cases of sarcoidosis and of controls. This study was undertaken in the mid-1980s, before sophisticated immunological testing became commonly used. The data, although collected several years ago, are now being reported as there is a renewed interest in beryllium exposure and also a paucity of published studies of beryllium in lung tissues.
The objectives of this report were:
1. to measure the concentration of beryllium in the lungs, to determine if the measurements could distinguish between the case of CBD, the cases of sarcoidosis and the controls; 2. to determine if the measurements could assist in the adjudication of claims for compensation for occupational CBD; 3. to compare and contrast the results of this study to those reported in the literature.
Materials and methods

Materials
Blocks of formalin-fixed lung tissue measuring~1.5 × 1.5 × 0.5 cm were taken from lungs of 29 patients coming to autopsy. The specimens were from one patient with CBD, three patients with clinically confirmed sarcoidosis and 25 without CBD or sarcoidosis, who were considered to be controls. Three of the controls were miners, or had worked for a time underground in a mine and one control had been a president of an electronics company.
CBD case
This patient was born in 1930. During the 1950s, he was exposed to beryllia powder and dust, for~6 years, while working in a factory that manufactured fluorescent light bulbs. He was well until December 1959, when an X-ray showed lesions in his lungs. At that time, he had no symptoms, but during the next few years as his lung disease worsened, he developed increasing shortness of breath. In 1981, he developed pneumonia and died in early 1982, at age 52. An autopsy showed beryllium disease in his lungs with severe and widespread fibrosis and with severe superimposed pneumonia.
Methods
All samples were analysed at McMaster University's Occupational and Environmental Health Laboratory, an American Industrial Hygiene Association (AIHA) accredited facility, using a Perkin-Elmer Model 703 atomic absorption spectrophotometer (AAS) equipped with an HGA-500 graphite furnace, deuterium background correction and an autosampler. NIOSH 7102 [16] , a method for analysis of beryllium in air samples, was modified to permit tissue analysis. In NIOSH 7102, 10 ml of concentrated nitric acid (HNO 3 ) and 1 ml of concentrated sulphuric acid (H 2 SO 4 ) are used to ash the filter samples. In our procedure, 3 ml of HNO 3 and 1 ml of 70% perchloric acid (HClO 4 ) were used to digest the tissue samples. Perchloric acid is a strong oxidizing agent, commonly used for tissue digestions. Sulphuric acid was not used in the digestions because losses were observed during the method development segment of this project. It was postulated that beryllium sulphate was formed during the digestion step. Beryllium sulphate would be lost during the ashing step, as it decomposes between 550 and 600°C. The standards were prepared by dilution of a 1000 µg/ml beryllium standard. The details of the furnace condition used in the analysis are available from the authors.
A weighed amount of wet tissue (~0.5 g) was placed in a 100 ml borosilicate glass beaker and 3 ml of concentrated nitric acid and 1 ml of 70-72% perchloric acid were added. The beaker was covered with a watch glass and digested on a hotplate at 130-150°C in a perchloric acid fumehood. The samples were digested until the organic matrix was destroyed and a clear solution remained. The samples were taken to dryness, then the sample residue was dissolved in a minimum volume of 1% nitric acid. The samples were quantitatively transferred to 10 ml volumetric flasks and analysed for beryllium using flameless atomic absorption spectrophotometry. The analyst was blind to the identity of the samples.
Results
In Table 1 , results of analysis of the tissue samples are given, along with available information such as occupation and sex. The concentration of beryllium in the tissues is reported as µg/g of dry tissue, a value obtained by using the dry-to-wet ratio of 0.15, an average value determined from our other lung dust study [17] . In Table 2 , the data from this study have been summarized, along with those reported by others [1, [18] [19] [20] [21] [22] [23] .
Discussion
The mean concentration of beryllium in the lungs of the patient with CBD was higher than the levels in the patients with sarcoidosis and the controls. Some of the individual values found in this patient were, however, within the range found in the patients with sarcoidosis and the controls. The lowest value for our CBD case, 0.100 µg/g, is within the range of the values for controls. As shown in Table 2 , the concentrations of beryllium in the lungs of CBD cases, measured in µg/g of dry tissues, have been reported to range between 0.004 and 45.7 by Sprince et al. [20] , between 0.023 and 0.093 by Karkinen-Jaaskelailnen et al. [22] , and between 0.02 and 15 by Jones William [24] . The results of our case, with an average of 0.360 µg/g, fall at the lower end of the values reported in the literature. Data in the other studies likely included cases of CBD with long and high exposure to beryllium [1, 20] . Jones Williams [24] considered positive tissue analysis an essential criterion for the diagnosis of CBD, along with a history of beryllium exposure and consistent clinical and radiological findings. In our case, the tissue analysis was positive. The demonstration of a high concentration of beryllium in the lungs alone, in the absence of compatible clinical and radiological findings and, preferably, pathological confirmation, does not justify a diagnosis of CBD. There are other forms of beryllium disease and other forms of pulmonary disease that can exist in people exposed to beryllium. A good occupational history is extremely valuable, but is not always possible to obtain, especially in patients coming to autopsy. The next of kin are often unaware of possible exposure to beryllium in the workplace. Karkinen-Jaaskelailnen et al. [22] were able to confirm a diagnosis of CBD in a patient with a low amount of beryllium in the lung (0.023 and 0.093 µg/g dry tissue) and only 1 month of occupational exposure to beryllium. This demonstrates the importance of obtaining accurate occupational exposure history for potential CBD cases.
Analysis for beryllium alone cannot distinguish between sarcoidosis and CBD, though one would expect that a patient with sarcoidosis would have a low concentration of beryllium in the lungs. A diagnosis of sarcoidosis, as with a diagnosis of CBD, depends primarily on the clinical, radiological and pathological findings, though knowledge of the level of beryllium in the tissues is always valuable, especially in raising the possibility of an uncommon condition such as CBD. Knowledge of the beryllium level in the lungs is especially valuable if a reliable occupational history cannot be obtained. If sampling is adequate, a low value almost excludes CBD, while a high value means that the possibility of CBD must be seriously considered.
When performing tissue analysis to aid in diagnosing CBD, it is important to include controls. Controls should be selected with care. In this particular study (see Table 2 ), the president of an electronics company, classified as a control, had a substantially higher level (an average of 0.239 µg/g) relative to the entire control group (an average of 0.077 µg/g). We speculate that the subject may have been exposed to beryllium, since it was widely use in the electronics industry. Unfortunately, there is no additional exposure information available for this case. Underground miners should not be used as controls, since as a group they have a slightly higher level (an average of 0.112 µg/g) than the remaining controls (an average of 0.065 µg/g). It is possible that there may be traces of beryllium in the Ontario underground rock formations where these hardrock (gold, uranium, nickel) miners worked. Coal miners in West Virginia have been shown to have fairly significant amounts of beryllium in their lungs, with an average of 0.6 µg/g reported, which is higher than levels found in our case and the cases reported by others (see Table 2 ). The patients with sarcoidosis generally had lower levels (an average of 0.058 µg/g) and were similar to the remaining controls (an average of 0.065 µg/g). It is important that several samples be analysed for diagnosis because of inhomogeneous distribution and highly variable concentration of beryllium in lung tissue. Lung tissue analysis for beryllium helped confirm the diagnosis of a compensatable CBD in this particular case.
